LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
The study will assess the safety, tolerability, PK and efficacy of different intra-tumoral
dosing regimens of LTX-315; a lytic-peptide that induces long-term anti-cancer immune
responses, as monotherapy or in combination with ipilimumab or pembrolizumab.